Skip to main content
Erschienen in: Molecular Neurodegeneration 1/2013

Open Access 01.09.2013 | Poster presentation

RAGE targeted strategies for Alzheimer’s amyloid β peptide induced blood brain barrier dysfunctions

verfasst von: Sholpan Askarova, Andrey Tsoy, James C-M Lee

Erschienen in: Molecular Neurodegeneration | Sonderheft 1/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Blood-brain barrier (BBB) dysfunctions have been implicated in the development and progression of Alzheimer’s disease. Cerebral endothelial cells (CECs) and astrocytes are the main cell components of the BBB. Although amyloid-β oligomers have been reported to mediate oxidative damage to the CECs and astrocytes and trigger the downstream MAPK/ERK pathway, the cell surface binding site for Aβ and exact sequence of these events have yet to be elucidated. In this study, the receptor for advanced glycation endproducts (RAGE) was postulated to function as a signal transducing cell surface receptor for Aβ to induce ROS generation from NADPH oxidase and trigger downstream pathways for the phosphorylation of extracellular-signal-regulated kinases (ERK1/2) and cytosolic phosphorilase A2 (cPLA2).

Materials and methods

Immortalized CECs (bEnd3) and primary rat astrocytes were applied in this study. To confirm Aβ-RAGE binding, we examined the quantitative immunofluorescence microscopy (QIM) of cellular surface RAGE for primary astrocytes and bEnd3 cells pretreated with oligomeric Aβ1-42 at +4°C (conditions in which the internalization of surface receptors is suppressed) and stained with antiRAGE primary antibody (AbRAGE). To quantify the ROS production, we applied fluorescence microscopy of dihydroethidium (DHE) in the cells. Confocal immunofluorescence microscopy of double immunofluorescent labeled gp91-phox and p47-phox subunits was performed to characterize NADPH oxidase complex assembly. Western blot analysis was applied to characterize phosphorylation of cPLA2α.

Results

We report that Aβ42 competed with the anti-RAGE antibody (AbRAGE) to bind to RAGE on the surfaces of CECs and primary astrocytes. In addition, AbRAGE abrogate Aβ42-induced ROS production and the co-localization between the cytosolic (p47-phox) and membrane (gp91-phox) subunits of NADPH oxidase in both cell types. AbRAGE, as well as NADPH oxidase inhibitor and ROS scavenger suppressed Aβ42-induced ERK1/2 and cPLA2 phosphorylation in CECs. At the same time, only AbRAGE, but not NADPH oxidase inhibitor or ROS scavenger, inhibited ERK1/2 and cPLA2α phosphorylation in primary astrocytes.

Conclusions

This study demonstrated that Aβ42 binding to RAGE on the CEC and astrocyte surfaces is required for NADPH oxidase complex assembling, resulting in subsequent ROS generation and phosphorylation of ERK1/2 and cPLA2 and suggested the presence of two different RAGE-dependent downstream pathways in CECs and astrocytes. Therefore, understanding precise molecular mechanisms underlying Aβ mediated oxidative damage may provide new insights into the development of preventive and treatment strategies for AD.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​ ) applies to the data made available in this article, unless otherwise stated.
Metadaten
Titel
RAGE targeted strategies for Alzheimer’s amyloid β peptide induced blood brain barrier dysfunctions
verfasst von
Sholpan Askarova
Andrey Tsoy
James C-M Lee
Publikationsdatum
01.09.2013
Verlag
BioMed Central
Erschienen in
Molecular Neurodegeneration / Ausgabe Sonderheft 1/2013
Elektronische ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-S1-P5

Weitere Artikel der Sonderheft 1/2013

Molecular Neurodegeneration 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.